.Nature Medication, Posted online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized period 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) therapy of people along with HER2+ sophisticated breast cancer cells as well as energetic or stable human brain metastases showed regular intracranial task as well as systemic efficiency of T-DXd.